# Agape ATP Corp: overview ATPC · Nasdaq · CIK 1713210 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atpc.md) · [Financials](/companies/atpc/financials.md) · [Filings](/companies/atpc/filings.md) · [Insiders](/companies/atpc/insiders.md) Latest reported revenue: [$13.7k](/filings/0001493152-26-037992.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037992). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [331](/filings/0001493152-25-022092.md) | [360 d](/filings/0001493152-26-016297.md) | [289](/filings/0001493152-26-023388.md) | [207](/filings/0001493152-26-037992.md) | [371](/filings/0001493152-25-022092.md) | [399 d](/filings/0001493152-26-016297.md) | [274](/filings/0001493152-26-023388.md) | [13.7](/filings/0001493152-26-037992.md) | | Gross margin | % | [55.6%](/filings/0001493152-25-022092.md) | [49.5% d](/filings/0001493152-26-016297.md) | [54.1%](/filings/0001493152-26-023388.md) | [31.6%](/filings/0001493152-26-037992.md) | [64.5%](/filings/0001493152-25-022092.md) | [58.6% d](/filings/0001493152-26-016297.md) | [58.3%](/filings/0001493152-26-023388.md) | [86.0%](/filings/0001493152-26-037992.md) | | Operating margin | % | [(165.4%)](/filings/0001493152-25-022092.md) | [(235.7%) d](/filings/0001493152-26-016297.md) | [(249.2%)](/filings/0001493152-26-023388.md) | [(300.2%)](/filings/0001493152-26-037992.md) | [(162.3%)](/filings/0001493152-25-022092.md) | [(325.2%) d](/filings/0001493152-26-016297.md) | [(247.5%)](/filings/0001493152-26-023388.md) | [(4023.8%)](/filings/0001493152-26-037992.md) | | Net margin | % | [(153.8%)](/filings/0001493152-25-022092.md) | [(224.7%) d](/filings/0001493152-26-016297.md) | [(246.7%)](/filings/0001493152-26-023388.md) | [(301.0%)](/filings/0001493152-26-037992.md) | [(158.3%)](/filings/0001493152-25-022092.md) | [(94.4%) d](/filings/0001493152-26-016297.md) | [(124.6%)](/filings/0001493152-26-023388.md) | [1091.3%](/filings/0001493152-26-037992.md) | | Diluted EPS | $ per share | [(0.13)](/filings/0001493152-25-022092.md) | not reported | [(3.63)](/filings/0001493152-26-023388.md) | [(0.62)](/filings/0001493152-26-037992.md) | [(0.01)](/filings/0001493152-25-022092.md) | not reported | [(0.33)](/filings/0001493152-26-023388.md) | [0.15](/filings/0001493152-26-037992.md) | | Free cash flow | $k | not reported | not reported | [(1,455)](/filings/0001493152-26-023388.md) | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,017](/filings/0001493152-23-010029.md) | [1,857](/filings/0001493152-24-012467.md) | [1,431](/filings/0001641172-25-001611.md) | [1,323](/filings/0001493152-26-016297.md) | [1,524](/filings/0001493152-26-016297.md) | | Gross margin | % | [70.8%](/filings/0001493152-23-010029.md) | [64.1%](/filings/0001493152-24-012467.md) | [65.4%](/filings/0001641172-25-001611.md) | [57.4%](/filings/0001493152-26-016297.md) | [55.0%](/filings/0001493152-26-016297.md) | | Operating margin | % | [(182.8%)](/filings/0001493152-23-010029.md) | [(82.6%)](/filings/0001493152-24-012467.md) | [(150.0%)](/filings/0001641172-25-001611.md) | [(194.5%)](/filings/0001493152-26-016297.md) | [(213.7%)](/filings/0001493152-26-016297.md) | | Net margin | % | [(248.2%)](/filings/0001493152-23-010029.md) | [(90.9%)](/filings/0001493152-24-012467.md) | [(146.9%)](/filings/0001641172-25-001611.md) | [(186.8%)](/filings/0001493152-26-016297.md) | [(149.6%)](/filings/0001493152-26-016297.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-22-007862.md) | [(0.02)](/filings/0001493152-24-012467.md) | [(0.55)](/filings/0001641172-25-001611.md) | [(31.74)](/filings/0001493152-26-016297.md) | [(2.85)](/filings/0001493152-26-016297.md) | | Free cash flow | $k | [(850)](/filings/0001493152-23-010029.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atpc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $136.0k | 45,934 | | Added +22,274 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $174 | 58,846 | | New +58,846 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $24 | 8 | | Reduced −2,582 | ## Recent filings [All 168 filings](/companies/atpc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 08:16 ET | [10-Q](/filings/0001493152-26-037992.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037992 | | 2026-07-20 | 13:45 ET | [S-1/A](/filings/0001493152-26-033881.md) | Registration statement, amended | 0001493152-26-033881 | | 2026-06-08 | 12:00 ET | [S-1](/filings/0001493152-26-027669.md) | Registration statement | 0001493152-26-027669 | | 2026-05-15 | 08:44 ET | [10-Q](/filings/0001493152-26-023388.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023388 | | 2026-04-13 | 08:46 ET | [10-K](/filings/0001493152-26-016297.md) | Annual report, period 2025-12-31 | 0001493152-26-016297 | | 2026-03-12 | 09:00 ET | [8-K](/filings/0001493152-26-009790.md) | 3.01 Delisting notice | 0001493152-26-009790 | | 2026-03-10 | 09:00 ET | [8-K](/filings/0001493152-26-009469.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-009469 | | 2026-02-06 | 11:00 ET | [8-K](/filings/0001493152-26-005471.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-005471 | | 2026-02-05 | 09:00 ET | [8-K](/filings/0001493152-26-005211.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-005211 | | 2026-02-02 | 09:22 ET | [8-K](/filings/0001493152-26-004669.md) | 5.07 Shareholder vote results | 0001493152-26-004669 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-016297.md), filed Apr 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9c5d126d-38e2-419f-b14d-dc18cbaad94b) ## About the filer - CIK: 1713210 - Tickers: ATPC - Exchange: Nasdaq - SIC code: 8000 Services-Health Services - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.